MBX Share Price Performance
Recent MBX News & Updates
No updates
Microbix Biosystems Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.011
- Gross Margin
- 57.74%
- Net Profit Margin
- 6.89%
- Debt/Equity Ratio
- 15.2%
Microbix Biosystems Inc. Competitors
About MBX
- Founded
- 1988
- Employees
- n/a
- CEO
- WebsiteView website
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
Canadian Market Performance
- 7 Days: -1.8%
- 3 Months: 7.8%
- 1 Year: 18.5%
- Year to Date: 8.6%
Over the last 7 days, the market has dropped 1.8%, driven by declines in every sector, especially the Financials sector. In contrast to the last week, the market is actually up 19% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading